Recombinant SP-D Formulation Oligomerization Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pulmonary surfactant formulations lack the ability to effectively modulate the host immune response due to the loss of hydrophilic surfactant proteins like SP-D during purification, which is crucial for therapeutic efficacy in treating pulmonary diseases.
Innovation Solution
A pharmaceutical composition comprising recombinant human surfactant protein D (rhSP-D) with specific concentrations of histidine, lactose, and calcium chloride, formulated to maintain appropriate oligomerization states for enhanced immune modulation and stability, including a lyophilized form suitable for pulmonary administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of substance
If traditional purification methods are used for surfactant formulations, then the purification process is simple, but SP-D is lost due to hydrophilic properties
Solution Approach 1:
The patent modifies purification parameters by adjusting pH to specific ranges (6.0-7.4) and ionic strength conditions to prevent SP-D loss while maintaining purification effectiveness. This resolves the contradiction by changing process parameters rather than simplifying the process.
Solution Approach 2:
The patent uses composite purification approaches combining multiple steps including affinity chromatography, ion exchange, and size exclusion chromatography. This composite method preserves SP-D while achieving thorough purification.
2Reliability
If SP-D is included in surfactant formulations, then immune modulation capability is improved, but formulation complexity increases
Solution Approach 1:
The patent formulates SP-D with multiple functionalities: immune modulation, surfactant stabilization, and pathogen agglutination. This multi-functional approach justifies the formulation complexity by providing multiple therapeutic benefits simultaneously.
Solution Approach 2:
The patent uses specific excipients and buffers as intermediaries to stabilize SP-D and facilitate its integration into surfactant formulations. These intermediaries enable SP-D inclusion while managing formulation complexity.
3Reliability
If oligomerization state is maintained, then therapeutic efficacy is improved, but manufacturing precision requirements increase
Solution Approach 1:
The patent controls oligomerization by adjusting physical-chemical parameters including pH, ionic strength, and protein concentration during manufacturing. These parameter changes enable precise control of oligomerization state to maintain therapeutic efficacy.
Solution Approach 2:
The patent implements quality control measures with feedback mechanisms to monitor and adjust oligomerization state during production. This ensures consistent therapeutic efficacy while managing manufacturing precision requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation ensures improved therapeutic efficacy by maintaining the correct oligomerization state of SP-D, enhancing its immune modulatory and antimicrobial activities, and providing stability for prolonged shelf-life.
Implementation Method 1
An important characteristic of native SP-D that must be maintained in any pharmaceutical composition is the appropriate oligomerization state because the higher-order multimerization in the endogenous surfactant protein increases the number of SP-D-binding sites to carbohydrate ligands on the surface of pathogens
Implementation Method 2
Some such embodiments include solutions, and lyophilized solid forms of recombinant human surfactant protein D or active fragments thereof
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Some embodiments provided herein relate to methods and pharmaceutical compositions comprising recombinant human surfactant protein D or active fragments thereof. Some such embodiments include solutions or suspensions, and lyophilized solid forms of recombinant human surfactant protein D or active fragments thereof.